» Articles » PMID: 38010438

Atrial Fibrillation, Electroconvulsive Therapy, Stroke Risk, and Anticoagulation

Overview
Journal Egypt Heart J
Publisher Springer
Date 2023 Nov 27
PMID 38010438
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Electroconvulsive therapy (ECT) is a therapy used to treat refractory mental health conditions, ranging from depression to catatonia, and it has gained renewed prominence in practice and the literature of late. Given that ECT involves the application of direct current to the body, there exists a risk of a change in cardiac rhythm during therapy. When atrial fibrillation is induced, ECT carries a potential risk of stroke. These risks have not been previously analyzed or summarized in the literature to allow physicians to make educated decisions about periprocedural risk and anticoagulation needs.

Methods: To better describe this risk, the authors reviewed PubMed for articles that described the post-ECT cardioversion of AF to sinus rhythm, new development of AF post-ECT, and new stroke after either rhythm change.

Results: Included were 14 studies describing 19 unique patients. Most patients had no rhythm change during at least one of many ECT sessions. Five patients converted from AF to sinus rhythm during at least one session, while AF followed ECT in seventeen patients during at least one ECT session. Four patients experienced both ECT-related cardioversion from AF to sinus rhythm as well as conversion from sinus rhythm to AF. Although no patients with a rhythm change experienced a stroke, one unanticoagulated patient who remained in AF developed a stroke post-ECT.

Conclusions: Electroconvulsive therapy is demonstrated to be associated with rhythm changes-from atrial fibrillation to sinus rhythm as well as from sinus rhythm to atrial fibrillation. Thus, stroke risk during and after ECT remains a possibility. The anticoagulation of patients with AF who undergo ECT should be based on individual stroke risk factors, using validated stroke risk models, rather than prescribed routinely.

Citing Articles

Comparison between non-vitamin K oral antagonist versus warfarin in atrial fibrillation with and without valvular heart disease: a systematic review and meta-analysis.

Adji A, de Liyis B Egypt Heart J. 2024; 76(1):102.

PMID: 39120758 PMC: 11315858. DOI: 10.1186/s43044-024-00535-w.

References
1.
Schmidt S, Lapid M, Sundsted K, Cunningham J, Ryan D, Burton M . Safety of electroconvulsive therapy in patients receiving dabigatran therapy. Psychosomatics. 2013; 55(4):400-403. DOI: 10.1016/j.psym.2013.06.010. View

2.
Perez M, Mahaffey K, Hedlin H, Rumsfeld J, Garcia A, Ferris T . Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation. N Engl J Med. 2019; 381(20):1909-1917. PMC: 8112605. DOI: 10.1056/NEJMoa1901183. View

3.
Workman A . Cardiac adrenergic control and atrial fibrillation. Naunyn Schmiedebergs Arch Pharmacol. 2009; 381(3):235-49. PMC: 2855383. DOI: 10.1007/s00210-009-0474-0. View

4.
Lip G, Nieuwlaat R, Pisters R, Lane D, Crijns H . Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2009; 137(2):263-72. DOI: 10.1378/chest.09-1584. View

5.
Eagle K, Berger P, Calkins H, Chaitman B, Ewy G, Fleischmann K . ACC/AHA Guideline Update for Perioperative Cardiovascular Evaluation for Noncardiac Surgery--Executive Summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996.... Anesth Analg. 2002; 94(5):1052-64. DOI: 10.1097/00000539-200205000-00002. View